Regulatory Submission Process
The regulatory submission process transforms clinical trial data into a formal application for marketing authorization of a new drug.
## Submission Types
### New Drug Application (NDA)
An NDA is submitted to the FDA for approval of a new small-molecule drug. It contains all preclinical, clinical, manufacturing, and labeling data generated during development. The NDA is the formal request for permission to market the drug in the United States.
### Biologics License Application (BLA)
A BLA is the equivalent submission for biological products (monoclonal antibodies, vaccines, gene therapies, blood products). BLAs require additional characterization of the manufacturing process because biologics are defined by their production method.
### Abbreviated New Drug Application (ANDA)
ANDAs are submitted for generic drugs and rely on bioequivalence data rather than full clinical efficacy trials, referencing the safety and efficacy data of the approved reference product.
## Common Technical Document (CTD)
All major regulatory agencies accept submissions in the CTD format, organized into five modules:
- **Module 1**: Regional administrative information (not harmonized)
- **Module 2**: CTD summaries -- quality, nonclinical, and clinical overviews and summaries
- **Module 3**: Quality data (manufacturing, controls, stability)
- **Module 4**: Nonclinical study reports (pharmacology, toxicology)
- **Module 5**: Clinical study reports (all Phase I-III data)
Electronic submissions (eCTD) are mandatory for FDA and EMA, enabling structured navigation and lifecycle management of the dossier.
## FDA Review Process
### Filing Review (60 Days)
The FDA determines whether the submission is sufficiently complete for substantive review. A refusal to file requires major deficiencies to be addressed before resubmission.
### Review Timelines
- **Standard Review**: 10-month target (12 months for BLAs) for drugs offering incremental benefit
- **Priority Review**: 6-month target (8 months for BLAs) for drugs treating serious conditions with meaningful therapeutic advances
### Advisory Committee Meetings
The FDA may convene an advisory committee of independent experts to publicly discuss the application. Committee votes are advisory, not binding, but the FDA follows their recommendations approximately 75% of the time.
### Complete Response Letter
If the FDA identifies deficiencies preventing approval, it issues a Complete Response Letter (CRL) detailing what must be addressed. The applicant can respond, request a meeting, or withdraw the application.
## Accelerated Pathways
- **Fast Track**: Facilitates development with more frequent FDA communication
- **Breakthrough Therapy**: Intensive FDA guidance for drugs showing substantial improvement over existing treatments
- **Accelerated Approval**: Allows approval based on surrogate endpoints with required confirmatory trials
- **Priority Review**: Shortened review timeline
## Key Takeaways
- NDAs (small molecules), BLAs (biologics), and ANDAs (generics) are the three submission types
- The CTD format standardizes submissions across global regulatory agencies
- Standard FDA review takes 10 months; priority review takes 6 months
- Advisory committees provide expert input but their recommendations are not binding
- Four accelerated pathways exist for drugs addressing serious unmet medical needs